Canadian Pharmacy Blog

Decitabine injection (Dacogen, MGI Pharma, Inc./SuperGen, Inc.) has been approved by the U.S. Food and Drug Administration (FDA) for patients with myelodysplastic syndromes (MDS). MDS comprises a group of bone marrow diseases characterized by the production of poorly functioning and immature blood cells. Over time, MDS can progress to acute leukemia. A phase 3 clinical [...]

The FDA has approved a New Drug Application (NDA) supplement to add intravenous (IV) use as a new route of administration for azacitidine (Vidaza, Pharmion). This agent, which is indicated for the treatment of myelodys-plastic syndromes (MDS), may now be infused over a period of 10 to 40 minutes in a clinic or hospital setting. [...]